Abstract
Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Current Pharmaceutical Design
Title: Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Volume: 16 Issue: 26
Author(s): Kursat Tigen and Cihan Cevik
Affiliation:
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Abstract: Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Export Options
About this article
Cite this article as:
Tigen Kursat and Cevik Cihan, Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?, Current Pharmaceutical Design 2010; 16 (26) . https://dx.doi.org/10.2174/138161210793176473
DOI https://dx.doi.org/10.2174/138161210793176473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Patents Relating to Therapeutic Angiogenesis Using Endothelial Progenitors and Other Vasculogenesis-Related Cell Types
Recent Patents on Regenerative Medicine Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?
Current Cardiology Reviews A Narrative Review of Recent Studies on the Role of Vitamin D in the Prevention of Cardiac and Renal Risk and Additional Considerations for COVID-19 Vulnerability
Current Vascular Pharmacology The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Use of Contrast Echocardiography in Intensive Care and at the Emergency Room
Current Cardiology Reviews Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Vascular Oxidative Stress: A Key Factor in the Development of Hypertension Associated with Ethanol Consumption
Current Hypertension Reviews Metallothioneins and Cancer
Current Protein & Peptide Science Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design The LIM Protein fhlA is Essential for Heart Chamber Development in Zebrafish Embryos
Current Molecular Medicine Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Editorial (Thematic Issue: Calcium in Heart Disease: The Ubiquitous Ion)
Medicinal Chemistry